Søren Schou Olesen1,2, Henrik Krarup2,3, Jakob Lykke Poulsen1, Jeppe Hagstrup Christensen2,4, Andrea Rhiannon Glynne Sheel5,6, Robert Sutton5,6, William Greenhalf5, Christopher Halloran5,6, Asbjørn Mohr Drewes1,2. 1. Centre for Pancreatic Diseases, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark. 2. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 3. Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark. 4. Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark. 5. Department of Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool, UK. 6. Department of Pancreato-Biliary Surgery, The Royal Liverpool University Hospital, Liverpool, UK.
Abstract
Background: Pancreatic function testing and imaging are used to inform the diagnosis of chronic pancreatitis, but most of these methods are time- and cost-consuming or lack diagnostic accuracy. Objective: We investigated the utility of pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis. Design: This was a prospective study of 121 consecutive patients with chronic pancreatitis and a reference population of 94 healthy controls. Pancreas-specific plasma amylase level was determined and analysed for its association with exocrine pancreatic insufficiency, diabetes and other clinical variables. Receiver operating characteristic curve analyses were performed to determine the diagnostic utility of plasma amylase for diagnosing chronic pancreatitis and to study associations with disease severity. The findings were validated in a further cohort of 57 patients with chronic pancreatitis. Results: Significant and independent associations between plasma amylase level and duration of chronic pancreatitis as well as the presence of exocrine pancreatic insufficiency and diabetes were observed (all p < 0.001). An amylase level below 17.3 U/l had a high specificity (94%) and moderate sensitivity (59%) for the diagnosis of chronic pancreatitis. Diagnostic performance was influenced by disease stage with the best performance observed for advanced disease. The findings were replicated in the validation cohort. Conclusion: Pancreas-specific plasma amylase may provide a clinically useful mean for assessment and diagnosis of chronic pancreatitis.
Background: Pancreatic function testing and imaging are used to inform the diagnosis of chronic pancreatitis, but most of these methods are time- and cost-consuming or lack diagnostic accuracy. Objective: We investigated the utility of pancreas-specific plasma amylase for assessment and diagnosis of chronic pancreatitis. Design: This was a prospective study of 121 consecutive patients with chronic pancreatitis and a reference population of 94 healthy controls. Pancreas-specific plasma amylase level was determined and analysed for its association with exocrine pancreatic insufficiency, diabetes and other clinical variables. Receiver operating characteristic curve analyses were performed to determine the diagnostic utility of plasma amylase for diagnosing chronic pancreatitis and to study associations with disease severity. The findings were validated in a further cohort of 57 patients with chronic pancreatitis. Results: Significant and independent associations between plasma amylase level and duration of chronic pancreatitis as well as the presence of exocrine pancreatic insufficiency and diabetes were observed (all p < 0.001). An amylase level below 17.3 U/l had a high specificity (94%) and moderate sensitivity (59%) for the diagnosis of chronic pancreatitis. Diagnostic performance was influenced by disease stage with the best performance observed for advanced disease. The findings were replicated in the validation cohort. Conclusion: Pancreas-specific plasma amylase may provide a clinically useful mean for assessment and diagnosis of chronic pancreatitis.
Authors: David C Whitcomb; Luca Frulloni; Pramod Garg; Julia B Greer; Alexander Schneider; Dhiraj Yadav; Tooru Shimosegawa Journal: Pancreatology Date: 2016-02-16 Impact factor: 3.996
Authors: C Mel Wilcox; Dhiraj Yadav; Tian Ye; Timothy B Gardner; Andres Gelrud; Bimaljit S Sandhu; Michele D Lewis; Samer Al-Kaade; Gregory A Cote; Christopher E Forsmark; Nalini M Guda; Darwin L Conwell; Peter A Banks; Thiruvengadam Muniraj; Joseph Romagnuolo; Randall E Brand; Adam Slivka; Stuart Sherman; Stephen R Wisniewski; David C Whitcomb; Michelle A Anderson Journal: Clin Gastroenterol Hepatol Date: 2014-10-24 Impact factor: 11.382
Authors: P Maisonneuve; A B Lowenfels; B Müllhaupt; G Cavallini; P G Lankisch; J R Andersen; E P Dimagno; A Andrén-Sandberg; L Domellöf; L Frulloni; R W Ammann Journal: Gut Date: 2005-04 Impact factor: 23.059
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet; Herbert Y Kressel; Nader Rifai; Robert M Golub; Douglas G Altman; Lotty Hooft; Daniël A Korevaar; Jérémie F Cohen Journal: BMJ Date: 2015-10-28
Authors: Hyoung-Chul Oh; Chang-Il Kwon; Ihab I El Hajj; Jeffrey J Easler; James Watkins; Evan L Fogel; Lee McHenry; Stuart Sherman; Michelle K Zimmerman; Glen A Lehman Journal: Gut Liver Date: 2017-11-15 Impact factor: 4.519
Authors: Qiong Wei; Liang Qi; Hao Lin; Dechen Liu; Xiangyun Zhu; Yu Dai; Richard T Waldron; Aurelia Lugea; Mark O Goodarzi; Stephen J Pandol; Ling Li Journal: Front Physiol Date: 2020-10-28 Impact factor: 4.566